Get the Stockscreener App
0.1609
2.09%
0.0033
After Hours:
.16
-0.0009
-0.56%
In 8 Bio Inc stock is traded at $0.1609, with a volume of 466.72K.
It is up +2.09% in the last 24 hours and down -28.87% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
See More
Previous Close:
$0.1576
Open:
$0.1582
24h Volume:
466.72K
Relative Volume:
0.09
Market Cap:
$12.94M
Revenue:
-
Net Income/Loss:
$-31.88M
P/E Ratio:
-0.2145
EPS:
-0.75
Net Cash Flow:
$-25.20M
1W Performance:
+9.38%
1M Performance:
-28.87%
6M Performance:
-30.07%
1Y Performance:
-83.91%
1-Day Range:
$0.1568
$0.1649
1-Week Range:
$0.1452
$0.1749
52-Week Range:
$0.133
$1.74
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
0.1609 | 12.94M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-24 | Initiated | Laidlaw | Buy |
| Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
Tevogen Bio Signs Agreement with CD 8 Technology - TipRanks
TELA Bio to Announce First Quarter 2025 Financial Results - The Manila Times
Medical Tech Leader TELA Bio Schedules Q1 2025 Earnings: Key Growth Updates Expected - Stock Titan
Is Gossamer Bio Inc. (NASDAQ:GOSS) the Best Penny Stock to Invest in Under $1? - Insider Monkey
GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference - Yahoo Finance
Vyant Bio (OTCMKTS:VYNT) Trading 7.8% Higher – Time to Buy? - Defense World
Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace
Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108 - GlobeNewswire
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 8, 2025 - BioSpace
South Korean firms ABL Bio, Yuhan advance bispecific antibodies in cancer treatmentCHOSUNBIZ - Chosunbiz
High Growth Tech Stocks Including ABL Bio To Watch - Yahoo
ABL Bio lands $2.8 billion license-out deal with GSK - The Korea Economic Daily Global Edition
GRI Bio Reports Encouraging Interim 2-Week Safety Results - GlobeNewswire
GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) - Yahoo Finance
KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - TradingView
GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan - GlobeNewswire
SEC Form 424B5 filed by Instil Bio Inc. - Quantisnow
bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid - Yahoo Finance
Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference - The Globe and Mail
Healthcare Spotlight: Climb Bio Takes Center Stage at Major Needham Conference - Stock Titan
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program - Quantisnow
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results - Quantisnow
Entera Bio Ltd expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Kronos Bio Inc (KRON) Q4 2024 Earnings: EPS Misses at -$0.43, Re - GuruFocus.com
GRI Bio Reports Full Year 2024 Financial Results and - GlobeNewswire
Short Interest in bluebird bio, Inc. (NASDAQ:BLUE) Drops By 26.8% - Defense World
10 Most Oversold Penny Stocks to Buy According to Analysts - Insider Monkey
Analysts Set Nuvation Bio Inc. (NYSE:NUVB) Target Price at $8.33 - Defense World
Gossamer Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Palisade Bio Announces Two Abstracts Selected to be - GlobeNewswire
Shareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public Shareholders - Joplin Globe
GRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price Rule - GlobeNewswire
Why Paymentus Holdings Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket - Benzinga
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb - Business Wire
Nuvation Bio Inc. (NUVB): Among the Best NYSE Penny Stocks to Buy According to Analysts - Yahoo Finance
Q32 Bio Inc expected to post a loss of $1.51 a shareEarnings Preview - TradingView
Nuvation Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Passage Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Palisade Bio Participates in Virtual Investor “What This Means” Segment - GlobeNewswire
Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations - Yahoo Finance
Canadian North Resources Inc. Expands Metallurgical Programs Applying Low-carbon Footprint Bioleaching Technology on Ferguson Lake Ni-Cu-Co PGE project - Yahoo Canada Finance
Pre-market Movers: BTAI, VRPX, DCGO, NBY... - RTTNews
Global Nucleic Acid Amplification Testing Market to Grow Rapidly at an ~8% CAGR by 2032 | DelveInsight - GlobeNewswire
Genetic Medicine Pioneer Passage Bio Sets March Investor Conference Schedule - StockTitan
Title: bluebird bio Announces Positive Phase 1/2 Clinical Trial Data for Gene Therapy - Defense World
Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned - Yahoo Finance
What's Going On With Gene Therapy Company Bluebird Bio Stock Today? - Benzinga
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from - GlobeNewswire
Annovis to Host Patients' Live Forum on February 27, 2025 - Quantisnow
Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - The Globe and Mail
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):